Regnum Corp.

Equities

RGMP

US75915R1068

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:32:55 2024-02-16 EST			5-day change	1st Jan Change
0.0001 ^USD	-98.31%		-.--%	-98.31%

2023	Regnum Corp. Announces Resignation of Anne Kirby as Chief Executive Officer	CI
2023	Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of Directors	CI

Regnum Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019

November 05, 2019 at 02:38 pm

Regnum Corp. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced sales was USD 2,500 compared to USD 3,500 a year ago. Operating income was USD 88 compared to USD 249 a year ago. Net income was USD 88 compared to USD 147 a year ago. For the nine months, sales was USD 5,300 compared to USD 17,000 a year ago. Operating loss was USD 30,944 compared to operating Income of USD 3,426 a year ago. Net loss was USD 30,944 compared to net income of USD 2,190 a year ago.

Latest news about Regnum Corp.

Regnum Corp. Announces Resignation of Anne Kirby as Chief Executive Officer	23-05-30	CI
Regnum Corp. Announces Resignation of Anne Kirby as Sole Member of Board of Directors	23-05-30	CI
Regnum Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Martin Shkreli-founded drug company files for bankruptcy	23-05-10	RE
Regnum Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Regnum Corp. Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Regnum Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Regnum Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Regnum Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Regnum Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Regnum Signs Assignment and Assumption Agreement with CytoDyn and SevenScore Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV	22-01-10	CI
Regnum Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-23	CI
Regnum Corp. announced that it has received $1.5 million in funding from Phoenixus AG	21-10-07	CI
SevenScore Pharmaceuticals, LLC cancelled the acquisition of Regnum Corp. from Phoenixus AG in a reverse merger transaction.	21-08-31	CI
Regnum Corp. Reports Earnings Results for the Full Year Ended December 31, 2020	21-08-13	CI
Regnum Corp. Announces Management Changes	21-04-09	CI
Regnum Corp. Announces Management Changes	21-04-09	CI
Regnum Corp. Announces Management Changes	21-04-09	CI
SevenScore Pharmaceuticals LLC entered into an agreement to acquire Regnum Corp. in a reverse merger transaction for $9.8 million.	21-04-08	CI
Regnum Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2020	21-02-03	CI
Regnum Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-10-13	CI
Regnum Corp. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-04-29	CI
Regnum Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-14	CI
Regnum Corp. Announces Management Changes	20-03-31	CI
Regnum Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-05	CI

Chart Regnum Corp.

Duration

Period

More charts

Company Profile

Regnum Corp. is focused on developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges due to inconvenient dosing or delivery system, tolerability, or cost and accessibility of available therapeutic options. The Company's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. Leronlimab is a monoclonal antibody. The target of leronlimab is the immunologic receptor CCR5. Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells. The leronlimab antibody belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. Leronlimab blocks HIV from entering a cell by binding to a molecule called CCR5 referred to as R5 strains, attach as part of HIVs entry into a cell.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REGNUM CORP.	-98.31%	2.3K
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B

Other Biotechnology & Medical Research